| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/28/2023 | 56.77% | Piper Sandler | → $33 | Initiates Coverage On | → Overweight |
| 08/07/2023 | 18.76% | Mizuho | $29 → $25 | Maintains | Neutral |
| 08/03/2023 | 99.52% | Morgan Stanley | $46 → $42 | Maintains | Overweight |
| 08/03/2023 | 47.27% | B of A Securities | $36 → $31 | Downgrades | Buy → Neutral |
| 08/03/2023 | 94.77% | HC Wainwright & Co. | $45 → $41 | Maintains | Buy |
| 05/23/2023 | 42.52% | Goldman Sachs | $31 → $30 | Maintains | Neutral |
| 05/08/2023 | 37.77% | Mizuho | $26 → $29 | Maintains | Neutral |
| 05/04/2023 | 42.52% | Wells Fargo | → $30 | Upgrades | Equal-Weight → Overweight |
| 04/10/2023 | — | TD Cowen | Initiates Coverage On | → Outperform | |
| 04/03/2023 | 113.78% | HC Wainwright & Co. | → $45 | Reiterates | → Buy |
| 03/17/2023 | 37.77% | JP Morgan | $40 → $29 | Downgrades | Overweight → Neutral |
| 03/16/2023 | 4.51% | Berenberg | → $22 | Reinstates | → Hold |
| 03/09/2023 | 23.52% | Mizuho | $28 → $26 | Maintains | Neutral |
| 02/23/2023 | 90.02% | Morgan Stanley | $50 → $40 | Maintains | Overweight |
| 02/23/2023 | 113.78% | HC Wainwright & Co. | $48 → $45 | Maintains | Buy |
| 02/23/2023 | 42.52% | Wells Fargo | $38 → $30 | Downgrades | Overweight → Equal-Weight |
| 02/22/2023 | 47.27% | Goldman Sachs | $28 → $31 | Maintains | Neutral |
| 12/06/2022 | 90.02% | JP Morgan | $49 → $40 | Maintains | Overweight |
| 11/10/2022 | 33.02% | Mizuho | $32 → $28 | Maintains | Neutral |
| 11/09/2022 | 128.03% | HC Wainwright & Co. | $50 → $48 | Maintains | Buy |
| 11/01/2022 | 90.02% | Loop Capital | → $40 | Initiates Coverage On | → Buy |
| 10/20/2022 | 85.27% | B of A Securities | → $39 | Initiates Coverage On | → Buy |
| 09/29/2022 | 94.77% | Cantor Fitzgerald | → $41 | Initiates Coverage On | → Overweight |
| 09/26/2022 | 80.52% | Wells Fargo | → $38 | Initiates Coverage On | → Overweight |
| 09/21/2022 | 33.02% | Goldman Sachs | $24 → $28 | Maintains | Neutral |
| 09/13/2022 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 08/23/2022 | 52.02% | Mizuho | $27 → $32 | Maintains | Neutral |
| 08/22/2022 | 137.53% | Morgan Stanley | $39 → $50 | Maintains | Overweight |
| 08/09/2022 | 156.53% | Stifel | $50 → $54 | Maintains | Buy |
| 08/03/2022 | 28.27% | Mizuho | $30 → $27 | Maintains | Neutral |
| 07/07/2022 | 42.52% | Mizuho | → $30 | Initiates Coverage On | → Neutral |
| 05/24/2022 | -4.99% | Goldman Sachs | $28 → $20 | Maintains | Neutral |
| 02/15/2022 | 28.27% | Goldman Sachs | → $27 | Initiates Coverage On | → Neutral |
| 01/05/2022 | 137.53% | JP Morgan | → $50 | Initiates Coverage On | → Overweight |
| 12/16/2021 | 137.53% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
| 09/07/2021 | 85.27% | Morgan Stanley | $27 → $39 | Maintains | Overweight |
| 06/18/2021 | 28.27% | Morgan Stanley | → $27 | Initiates Coverage On | → Overweight |
| 12/10/2020 | 14.01% | Goldman Sachs | → $24 | Initiates Coverage On | → Buy |
| 11/23/2020 | -14.49% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 11/09/2020 | -19.24% | Stifel | → $17 | Initiates Coverage On | → Buy |
What is the target price for Cerevel Therapeutics Hldg (CERE)?
There is no price target for Cerevel Therapeutics Hldg
What is the most recent analyst rating for Cerevel Therapeutics Hldg (CERE)?
There is no analyst for Cerevel Therapeutics Hldg
When is the next analyst rating going to be posted or updated for Cerevel Therapeutics Hldg (CERE)?
There is no next analyst rating for Cerevel Therapeutics Hldg
Is the Analyst Rating Cerevel Therapeutics Hldg (CERE) correct?
There is no next analyst rating for Cerevel Therapeutics Hldg